why choose us

First received: November 07, 2023

Clinical Trial: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Triple Negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Brief Summary: The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.

Read more